Now I have a clear picture. Let me synthesize everything into the final review.

---

## Summary

This paper introduces HypoGeneAgent, an LLM-based framework that couples single-cell cluster annotation with resolution selection. The core idea is to use an LLM agent (GPT-o3 with retrieval and self-verification) to generate top-5 GO hypotheses per cluster, then compute intra-cluster agreement (ICS) and inter-cluster distinctiveness (ICD) from these hypotheses, combining them into a Resolution Score that selects the optimal Leiden resolution. The method is demonstrated on K562 Perturb-seq data (GEX and perturbation levels), selecting resolutions 0.4 and 0.5, respectively — choices that are compared against silhouette, modularity, and an enrichment-based adaptation.

## Strengths

- **Novel resolution selection framework.** Using LLM annotation consistency (ICS + ICD) to derive a Resolution Score for cluster resolution tuning is a genuinely original idea. No prior work closes the loop between functional annotation and clustering hyperparameter selection in this way. The definitions are mathematically clean and well-motivated (Section 3.4).

- **Thorough Stage 1 ablation of LLM configurations.** The paper benchmarks 5 LLMs (GPT-4o, GPT-o3, GPT-5, Gemini-2.0-flash, Gemini-2.5-pro), two prompt classes (general and hypothesis), three embedding methods, and temperature sweeps on 100 curated GOBP gene sets. The finding that GPT-o3 with a hypothesis prompt achieves the best performance and that confidence scores correlate with semantic accuracy (Figure S3) provides a solid foundation for the agent configuration used in Stage 2.

- **Clear, well-structured presentation.** The two-stage experimental design (benchmark → deploy), the formal definitions of ICS, ICD, and RS, and the side-by-side comparison with traditional metrics (silhouette, modularity, enrichment) make the paper easy to follow.

## Weaknesses

### Major

- **Self-referential evaluation without independent ground-truth validation.** The Resolution Score is built entirely from LLM-generated hypotheses: ICS measures how similar the agent's own top-5 guesses are, and ICD measures how different top-1 guesses are across clusters. The paper provides no evidence — beyond the same LLM's outputs — that the resolution selected by this score recovers biologically correct partitions. The paper claims superiority over traditional metrics (abstract, Section 5), but this claim rests entirely on internal consistency of the agent's own outputs, not on any external biological benchmark. This is the paper's central weakness.

- **The enrichment "validation" does not corroborate the agent's choice.** Section 4.4.3 is presented as independent validation: applying the same ICS/ICD/RS framework to GO enrichment results. However, Figure 6a shows the enrichment-based resolution score peaks at resolution 0.7, while the agent selected 0.4 (GEX) or 0.5 (perturbation). The paper states (line 292): "consider the reasonability of cluster numbers we expected, so the selected resolution can be 0.5 or 0.4, which is consistent with our previous selection." This reasoning is ad hoc — the enrichment analysis, if anything, suggests a different resolution, and the paper does not explain or reconcile the discrepancy. This undermines the claim that the enrichment analysis validates the agent's choice.

### Minor

- **ICS metric lacks diversity controls.** ICS measures the similarity of the agent's top hypothesis against its 2nd–5th hypotheses for the same cluster. If the LLM tends to produce thematically similar hypotheses regardless of input (a plausible failure mode), ICS would be high even for low-quality clusters. The paper does not examine the baseline similarity of hypotheses across unrelated gene sets or demonstrate that high ICS correlates with genuine biological homogeneity. Stage 1 provides indirect evidence (top-1 hypotheses match ground truth better than lower-ranked ones), but this does not directly address the concern for ICS as used in resolution selection.

- **Hyperparameter sensitivity analysis is incomplete.** The weight \(w = 1/3\) is chosen by a "small grid search" (Section 3.4), and Figure S5 is mentioned as showing variation across clusters. However, the paper does not report whether the selected optimal resolution changes with \(w\) — which is the critical question for reliability of the method.

- **Single-dataset evaluation for resolution selection.** The resolution selection claim is demonstrated on only one Perturb-seq dataset (K562). While the K562 dataset is a reasonable testbed, demonstrating the approach on additional datasets (different cell types, perturbation conditions) would substantially strengthen the generalizability claim.

- **Overstated claims relative to evidence.** The abstract claims the method establishes "LLM agents as objective adjudicators of cluster resolution" and the conclusion positions HypoGeneAgent as a "powerful, general-purpose tool." These claims are not supported by the current evidence, which consists of a single dataset and self-referential evaluation.

## Nice-to-Haves

- Adding a ground-truth experiment (e.g., simulated data with known cluster structure, or a dataset with expert-annotated cell types) where the agent-selected resolution can be compared to the known truth via ARI or similar metrics would transform the evaluation from self-referential to externally validated.
- Comparing against MultiK (which the paper cites but does not benchmark against) or a simple biology-aware baseline (e.g., selecting the resolution that maximizes per-cluster GO enrichment significance) would better position the contribution.
- Reporting whether the optimal resolution changes across reasonable values of \(w\) would address the robustness concern.

## Removed Points

These points are flagged to be removed; treat them with caution.

- **"No external validation" (harsh critic).** Too strong. Section 4.4.3 IS an attempt at external validation via GO enrichment. The real problem is that the validation attempt is weak and contradictory, not that it's absent. Kept as a major weakness but recharacterized.

- **"Must compare against simulated data with known cluster structure."** This is a nice-to-have, not a requirement for a proof-of-concept paper introducing a new paradigm. Moved to Nice-to-Haves.

- **"Missing appendix details" (harsh critic on missing proofs/supplementary).** The parser strips appendix sections; the original submission presumably contains them. Removed.

- **Strength Finder claim that "the enrichment peak aligns with the agent's selection."** This is factually inaccurate per the paper. Figure 6a peaks at 0.7 while the agent selects 0.4–0.5. This claimed strength is contradicted by the paper itself and has been removed.

- **Demand for confidence intervals on resolution score.** Single-run evaluation is standard for this type of analysis. Moved out.

- **Formatting nits, typos, parser artifacts.** Removed per hard rules.

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

- The most impactful revision would be to include even one ground-truth validation experiment. A simulated Perturb-seq dataset where the true number of functional modules is known, or a well-annotated scRNA-seq dataset with expert-labeled cell types, would allow computing whether the agent-selected resolution recovers true labels better than traditional metrics. This single addition would convert the paper's core weakness into a strength.
- Report a null baseline for ICS: compute the similarity between the agent's top-1 hypothesis from cluster A and its 2nd–5th hypotheses for cluster B (across clusters). This would establish whether ICS meaningfully exceeds a random-pairing baseline.
- Explicitly address the discrepancy between the enrichment-based RS peak (0.7) and the agent's selection (0.4–0.5), rather than glossing over it.

---

**Anchor comparison across all rounds:**

| Paper | Avg Score | Round | Comparison |
|---|---|---|---|
| scMPT (nUpM7egYFd) | 3.40 | R1-weak | Weaker — LLM as an alternative to scFMs, less novel framing |
| DrugAgent (PQrkWvQSL0) | 2.50 | R1-weak | Much weaker — multi-agent system with limited validation |
| scKGOT (Y9yQ9qmVrc) | 2.50 | R1-weak | Weaker — more standard method, lower novelty |
| LLM4GRN (jLd7OyAD4Y) | 4.33 | R1-mid, R2-narrow | Similar weakness profile (novel idea, insufficient validation). HypoGeneAgent has a more thorough Stage 1 but similar self-referential evaluation issues. Comparable but slightly weaker due to enrichment discrepancy. |
| ZerOmics (J1xtkJmFY3) | 4.67 | R1-mid, R2-narrow | Stronger — broader experimental scope, multiple tasks and datasets. HypoGeneAgent falls below this. |
| PerturbQA (5WEpbilssv) | 4.60 | R1-mid, R2-narrow | Stronger — provides a reusable benchmark, tests on multiple datasets. Accepted at 4.60. HypoGeneAgent is weaker due to self-referential evaluation and single-dataset scope. |
| Gene benchmark (GDDqq0w6rs) | 4.75 | R2-narrow | Stronger — comprehensive benchmark with systematic evaluation. Not directly comparable in type but higher in execution quality. |
| scFM retrieval (iOltCu4TPS) | 5.00 | R2-narrow | Stronger — more comprehensive evaluation scope, multi-method benchmark. |

**Bracketing:** Round 1 placed the paper between ~3.5 and ~5.5. Round 2 narrowed to ~4.0–4.7. Compared directly to LLM4GRN (4.33 — similar novel-idea/weak-validation profile), HypoGeneAgent has a more thorough Stage 1 ablation and a cleaner method but a more glaring contradiction in its enrichment validation. It falls clearly below PerturbQA (4.60, Accept) and the gene benchmark (4.75). I place it at **4.0**, near but below LLM4GRN due to the enrichment discrepancy actively undermining rather than merely failing to support the central claim.

MY FINAL SCORE: <score>4.0</score>
MY FINAL DECISION: <decision>Reject</decision>